Study finds no evidence linking paracetamol in pregnancy to autism

A Lancet systematic review and meta-analysis of 43 studies found no evidence that maternal paracetamol use during pregnancy increases the risk of autism, ADHD or intellectual disability; the analysis included hundreds of thousands of children.

A comprehensive review published in Lancet Obstetrics, Gynaecology and Women's Health found no link between taking paracetamol during pregnancy and a child later being autistic, having ADHD or an intellectual disability. The study pooled and re‑analysed results from 43 previous studies and included sibling-comparison data. It was led by Professor Asma Khalil of City St George's, University of London and involved researchers across Europe. The authors describe their work as the most rigorous analysis to date and say their findings should reassure pregnant women about the drug's safety when used as guided. Key findings: - The review found no evidence that maternal paracetamol use during pregnancy increases the risk of autism spectrum disorder, ADHD, or intellectual disability. - Researchers examined 43 studies and used sibling-comparison approaches, covering about 262,852 children assessed for autism, 335,255 for ADHD and 406,681 for intellectual disability. - The authors say familial and genetic factors, and the underlying illnesses that might prompt prolonged paracetamol use, are more plausible explanations for previously reported associations than a direct drug effect. - Study authors and UK health officials said paracetamol remains a recommended first-line option for treating pain or fever in pregnancy when taken as directed. Summary: The review aims to reassure pregnant women that paracetamol, when used as guided, was not associated with higher risks of autism, ADHD or intellectual disability in the analysed studies. Undetermined at this time.